NIBEC CO., LTD.
Financials
Valuation Metrics
NIBEC CO., LTD.'s Market Cap is ₩1694B. At end of 2025 it was ₩4269B. Ranked #953 of 2,421 in KR market (top 39%), #464 of 1,640 on KOSDAQ (top 28%), #107 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 169.38B KRW | KR#953/2,421 Sec#107/231 |
| Revenue | 22.60B KRW | KR#2,111/2,421 Sec#153/231 |
| Net Income | -45.4M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 64.54B KRW | KR#2,061/2,421 Sec#175/231 |
| Net Assets | 47.95B KRW | KR#1,936/2,421 Sec#161/231 |
| Employees | 96 | KR#1,670/2,421 Sec#130/231 |
| Value | ||
| P/B | 3.53x | KR#2,154/2,421 Sec#174/231 |
| P/S | 7.49x | KR#2,228/2,421 Sec#156/231 |
| FCF Yield | 2.56% | KR#1,020/2,421 Sec#66/231 |
| Profitability | ||
| ROE | -0.09% | KR#1,551/2,421 Sec#107/231 |
| ROA | -0.07% | KR#1,555/2,421 Sec#107/231 |
| Op. Margin | -8.43% | KR#1,954/2,421 Sec#132/231 |
| Revenue Growth | -32.68% | KR#2,233/2,421 Sec#197/231 |
| Financial Health | ||
| Debt Ratio | 34.62% | KR#681/2,421 Sec#80/231 |
| Total Debt | 15.75B KRW | KR#1,478/2,421 Sec#124/231 |
| FCF | 4.33B KRW | KR#941/2,421 Sec#66/231 |
| Cash | 22.00B KRW | KR#1,195/2,421 Sec#83/231 |
| Current Ratio | 3.39x | KR#485/2,421 Sec#70/231 |
| Performance | ||
| 1Y Return | -42.14% | KR#1,889/2,421 Sec#162/231 |
| 1M Return | -6.52% | KR#1,902/2,421 Sec#153/231 |
| From 52W High | -72.56% | KR#2,251/2,421 Sec#195/231 |
| 1Y MDD | -76.67% | KR#2,231/2,421 Sec#198/231 |
| Trading | ||
| Volume | 86,006 shares | KR#850/2,421 Sec#79/231 |
| Trading Value | 1.30B KRW | KR#654/2,421 Sec#66/231 |
| Foreign Own. | 2.87% | KR#1,327/2,421 Sec#119/231 |
| Per Share | ||
| EPS | -4 KRW | KR—/2,421 Sec—/231 |
| BPS | 4,218 KRW | KR#1,619/2,421 Sec#115/231 |
Company Info
NIBEC, established in 2004, was founded to commercialize research from the Seoul National University College of Dentistry's Intelligent Bio-Interface Engineering Research Center. The company develops peptide-based drugs, convergence biomaterials, and protein engineering technology-based drugs, leveraging peptide-based drug delivery systems and biomaterial technology for tissue regeneration. Its dental bio-regeneration materials are sold globally through Straumann and Nobel Biocare, having received NMPA sales approval in China in 2020. NIBEC is headquartered in Jincheon-gun, Chungcheongbuk-do.